

FORM 8-K

Section 8 – Other Events**Item 8.01 Other Events**

On July 10, 2006, Anticus International Corporation issued the following press release:

ANTICUS INTERNATIONAL CORPORATION**NEWS RELEASE**

July 10th 2006

SIGNIFICANT PROGRESS RESULTS IN DEADLINE WAVED

Anticus Corporation (Anticus) a public traded company on the OTC: BB exchange (trading symbol: ATCI. OB), is pleased, to announce that in consideration of the significant progress in the negotiations with two major suppliers of lactoserum, representatives of the licensor have waived the deadline provided for in the license agreement requiring that Anticus must enter into a long term supply agreement for processable lactose or sugars in amounts sufficient to operate twenty (20) standard six thousand (6000) liter per hour bioconversion towers no later than June 15th 2006.

Representatives of the licensor further added “The negotiations with different suppliers of the new raw materials necessary to feed our bioreactors have progressed sufficiently and we expect our objectives to be met shortly.”

Anticus has acquired the worldwide exclusive license to the microbiological process known as Prolactis, which through the use of a bioreactor provides, for the bioconversion of lactose and other sugar, into high proteins biomass, literally transforming waste and by products into water and yeast to be used in animal feed.

The process has been developed by Jacques Goulet, Ph.D., agr., professor at Laval University in Quebec City, Quebec, Michel Deblois, engineer, and Lucien Pomerleau, M.Sc., agr. Worldwide patents are pending.

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995. The statement in this release relating to completion of the acquisition and the positive direction are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the results anticipated by these forward –looking statements may not occur. Factors that could cause or contribute to such differences include, but are not limited to, contractual difficulties which may arise, the failure to obtain Anticus shareholders approval, the future market price of Anticus common stock and the ability to obtain the necessary financing.

Contact:

Anticus Corporation

Investor Relations

Sebastien Plouffe

Telephone: (514) 845-8509

E-Mail: sebastien.plouffe@sympatico.ca

Section 9 – Financial Statements and Exhibits**Section 9.01 Financial Statements and Exhibits**

Anticus International Corporation includes herewith the following exhibit:

Exhibit 10 – Material Definitive Contract

Agreement for acquisition of the worldwide exclusive license to the microbiological process known as “Prolactis”.

By and between Anticus International Corporation; Gilles Varin, President, and: Michel Deblois Technologies Inc., Michel Deblois, President, and Costal, Inc., Jacques Goulet, President, and Redal, Inc., Lucien Pomerleau, General Director

As Amended, June 15, 2006

English translation included, French document is primary.

The exhibit is provided in its French and English versions, as a combined document, with the French version presented first and the English following, as a matter of convenience. The French version is the controlling document. The English version has no legal effect..

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Anticus International Corporation

Date: July 10, 2006

By: \s\ Mr. Gilles Varin, President
Name: Mr. Gilles Varin
Title: President and Director